Ferumoxytol-enhanced Magnetic Resonance Imaging

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 185 participants.

Also called NCT02954510

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 185 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02954510
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02954510. Allocation not applicable; no masking; primary purpose diagnostic. Start 2017-02-01 (actual); primary completion 2023-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferumoxytol-enhanced Magnetic Resonance Imaging
Intervention (Drug)
ferumoxytol
Lead sponsor
Brigham and Women's Hospital (class: other)

Record details

Record id
cardio:ct-nct02954510
Content hash
fcc270840359e13d3afb4467812701113e04a1735ad4b976bf5b70329f5d646e